Kamada (NASDAQ:KMDA) Stock Rating Lowered by StockNews.com

Kamada (NASDAQ:KMDA) was downgraded by StockNews.com from a “strong-buy” rating to a “buy” rating in a note issued to investors on Tuesday.

Several other research analysts also recently commented on KMDA. Benchmark began coverage on shares of Kamada in a research note on Friday, March 21st. They issued a “buy” rating and a $15.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $11.00 target price on shares of Kamada in a research report on Thursday, March 6th.

Kamada Stock Performance

Shares of KMDA stock opened at $6.90 on Tuesday. The stock has a 50 day moving average price of $7.18 and a 200 day moving average price of $6.29. Kamada has a 52-week low of $4.74 and a 52-week high of $9.16. The firm has a market capitalization of $396.61 million, a P/E ratio of 24.64, a P/E/G ratio of 0.97 and a beta of 0.97.

Institutional Trading of Kamada

Hedge funds have recently added to or reduced their stakes in the business. Public Employees Retirement System of Ohio bought a new stake in shares of Kamada in the 3rd quarter valued at about $77,000. JPMorgan Chase & Co. bought a new position in Kamada in the fourth quarter worth approximately $67,000. Geode Capital Management LLC lifted its holdings in Kamada by 5.6% during the fourth quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company’s stock worth $178,000 after buying an additional 1,549 shares during the period. NewEdge Advisors LLC boosted its position in Kamada by 54.2% during the 4th quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company’s stock valued at $143,000 after acquiring an additional 8,260 shares in the last quarter. Finally, Aristides Capital LLC increased its holdings in shares of Kamada by 12.1% in the 4th quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company’s stock valued at $387,000 after acquiring an additional 6,850 shares during the period. 20.38% of the stock is owned by hedge funds and other institutional investors.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.